Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection

• Published in: Antiviral research 2009-02, Vol.81 (2), p.174-179
• Main Authors: Boutolleau, David, Deback, Claire, Bressollette-Bodin, Céline, Varnous, Shaida, Dhedin, Nathalie, Barrou, Benoît, Vernant, Jean-Paul, Gandjbakhch, Iradj, Imbert-Marcille, Berthe-Marie, Agut, Henri
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Biological and medical sciences; Blood - virology; Chemoprevention; Cytomegalovirus; Cytomegalovirus - drug effects; Cytomegalovirus Infections - prevention & control; DNA, Viral - blood; Drug Resistance, Viral; Female; Ganciclovir - analogs & derivatives; Ganciclovir - pharmacology; Ganciclovir - therapeutic use; High-risk for CMV infection; Humans; Infectious diseases; Male; Medical sciences; Middle Aged; Mutation, Missense; Pharmacology. Drug treatments; Resistance; Risk factors; Transplant recipients; Transplantation; Valganciclovir; Viral diseases; Viral Load; Viral Proteins - genetics
• ISSN: 0166-3542; 1872-9096
• DOI: 10.1016/j.antiviral.2008.11.003

In transplant recipients, cytomegalovirus (CMV) resistance to antivirals causes an increasing problem. Here we report the clinical, therapeutic, and virological characteristics of 11 cases of CMV resistance among transplant recipients at high-risk for CMV infection and receiving valganciclovir as a prophylactic, preemptive or maintenance therapy. Active CMV infection was monitored by viral DNA quantification in whole blood, and CMV resistance was assessed by UL97 and UL54 viral gene sequencing. For 10 patients, ganciclovir resistance detected after valganciclovir therapy was associated with one mutation within UL97 phosphotransferase located at codons 460 and 592–603, which constitutes a similar pattern of resistance to what has been reported previously in AIDS patients treated with valganciclovir. For the last patient, two mutations in UL97 and UL54 genes were identified. The start of valganciclovir maintenance treatment after an intravenous curative treatment while CMV DNA is still detectable in peripheral blood might represent a risk factor for the emergence of CMV resistance. The possible emergence of CMV resistance in transplant recipients at high-risk for CMV infection who receive valganciclovir therapy should be taken into account. Among those patients, CMV infection has to be closely monitored in order to detect promptly the emergence of drug-resistance.